Study of khadir compound in the management of Kitibha (psoriasis)

Phase 2

Not yet recruiting

• Conditions: Psoriasis, unspecified. Ayurveda Condition: Kitibha Psoriasis,

• Registration Number: CTRI/2022/02/040085
• Lead Sponsor: Department of Kayachikitsa Faculty of Ayurveda Institute of Medical Sciences

Brief Summary

Kitibha (Psoriasis) is a challenging disease with its chronic and relapsing nature. Many herbal and herbomineral preparations are given in the literature and there mechanism of action is also explained on the basis of Ayurvedic  terminology. The classical drugs used for treating  Kitibha (psoriasis) are needed to be evaluated clinically along with cellular level to understand the probable mode of action of drug in the patient. Also the safety and efficacy of the drug is needed to be evaluated.  So keeping in mind these points the study is planned to establish the safe, cost effective,  clinically effective shaman chikitsa.

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2022-01-30
• Study Start: 2022-02-15

Recruitment & Eligibility

• Status: Not Yet Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Patient diagnosed as psoriasis.
• Age from 17 to 70 years.
• Patient willing to participate in the research and voluntarily give written consent.

Exclusion Criteria

• Age less than 17 years and more than 70 years.
• Pregnant and lactating mothers 3.
• Patient receiving panchakarma therapy or other conventional medicine.4. Psoriatic complications.
• Patient of liver and kidney disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. CBC 2. ESR 3. TNF alpha, 4. CRP 5. Cytokines.	At initial visit of patient and repeated after 3 months of treatment.

Secondary Outcome Measures

Name	Time	Method
1. To evaluate the clinical effect of Khadir. 2. To evaluate the clinical effect of daruharidra. 3. To evaluate the clinical effect of nimb. 4 to evaluate the clinical effect of khadir, daruharidra and nimb in combination. 5. To evaluate the cell line study of khadir, daruharidra and nimb. Assessment scales are PASI score, IGA scale, Itching, Scaling, Erythema, Dryness, Roughness, Thickness.	3 months with 3 follow ups of one month each.

Trial Locations

Locations (1)

Sir Sunderlal Hospital BHU; 🇮🇳 Varanasi, UTTAR PRADESH, India

Sir Sunderlal Hospital BHU

🇮🇳Varanasi, UTTAR PRADESH, India

Dr OP Singh

Principal investigator

9415818732

gourimedico@rediffmail.com